FATE Fate Therapeutics
- 3.800
- -0.070-1.81%
- 3.880
- +0.080+2.11%
Fate Therapeutics News
Fate Therapeutics Currently Down 11 Consecutive Days, on Track for Record Losing Streak -- Data Talk
Fate Therapeutics, Inc. (FATE) is currently at $4.36, down $0.18 or 3.96% --Would be lowest close since Jan. 18, 2024, when it closed at $4.33 --Currently down 14 of the past 15 days --Currently do
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Danaher (DHR) and Roche Holding AG (OtherRHHVF)
Fate Therapeutics Currently Down 10 Consecutive Days, on Pace for Longest Losing Streak Since December 2022 -- Data Talk
Fate Therapeutics, Inc. (FATE) is currently at $4.58, down $0.21 or 4.29% --Would be lowest close since Jan. 26, 2024, when it closed at $4.56 --Currently down 13 of the past 14 days --Currently do
Wedbush Reiterates Neutral on Fate Therapeutics, Maintains $7 Price Target
Wedbush analyst David Nierengarten reiterates Fate Therapeutics with a Neutral and maintains $7 price target.
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B Cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Fate Therapeutics, Inc. (NASDAQ: FATE) today announced that two presentations will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.
Why Investors Shouldn't Be Surprised By Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Share Price Plunge
Fate Therapeutics, Inc. (NASDAQ:FATE) shares have retraced a considerable 28% in the last month, reversing a fair amount of their solid recent performance. The drop over the last 30 days has capped
Fate Therapeutics Files to Sell 3.64M Shares for Holders
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Disc Medicine (IRON) and Avita Medical (RCEL)
Needham: Reiterates that Fate Therapeutics (FATE.US) holds the rating.
Needham: Reiterates that Fate Therapeutics (FATE.US) holds the rating.
Needham Reiterates Hold on Fate Therapeutics
Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) with a Hold.
FATE, ALPN and RLAY Are Among After Hour Movers
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersRallybio (NASDAQ:RLYB) shares rose 31.9% to $2.15 during Wednesday's after-market session. The company's market cap stands at $81.2 million. Vera Therapeutics (NASDAQ:VERA) shares increased by
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripoten
Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?
Fate Therapeutics Is Maintained at Underperform by B of A Securities
Fate Therapeutics Is Maintained at Underperform by B of A Securities
B of A Securities Maintains Underperform on Fate Therapeutics, Raises Price Target to $6
B of A Securities analyst Tazeen Ahmad maintains Fate Therapeutics with a Underperform and raises the price target from $2 to $6.
Fate Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/28/2024 -19.46% B of A Securities $2 → $6 Maintains Underperform 03/19/2024 -6.04% HC Wainwright & Co.
Cautious Outlook on Fate Therapeutics: Sell Rating Maintained Amid Competitive and Validation Concerns
Analysis
Price Target
No Data
